FAQ.

Our Cell Therapy Research Facility

Thank you for your interest in our cell therapy research facility. As a research institution, we are dedicated to advancing the scientific understanding of specialized cell therapies derived from induced pluripotent stem cells (iPSC). However, it's important to note that we do not make any unsubstantiated therapeutic claims about the efficacy of our research.

​

Procedure Duration

The procedures involved in our research studies typically last 2-3 hours for a single low-dose cell administration. This time frame allows us to carefully monitor and collect data on the cellular processes under investigation.

​

Conditions Under Study

Our research explores the potential applications of iPSC-derived specialized cells in addressing a variety of conditions, such as paralysis, rheumatoid arthritis, sickle cell disease, Alzheimer's dementia, and Parkinson's disease. However, it's crucial to understand that our findings are still in the research and development stage and have not yet been validated for clinical use.

​

Comparison to Mesenchymal Stem Cell Therapy

In our research, we have observed that iPSC-derived specialized cells may offer a potentially safer and more effective treatment approach compared to traditional Mesenchymal stem cell (MSC) therapy. MSC therapy has been associated with the risk of unintended differentiation and tumor formation, which is an area of ongoing investigation in our research facility.

 

It's important to note that all of our research activities are conducted in compliance with relevant regulations and ethical guidelines to ensure the safety and integrity of our scientific investigations. We encourage you to stay informed about the latest developments in our research by visiting our website or contacting us directly.